SCHEMBL660761

SCHEMBL660761

CC1(C)C(=O)CCC1O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL660760 1.00
SCHEMBL10738039 0.86 MEN1 (0.36)
SCHEMBL2543405 0.86 MEN1 (0.36)
SCHEMBL18029845 0.76
SCHEMBL28158617 0.75 PTPN1 (0.35)
SCHEMBL23645791 0.72
SCHEMBL16383081 0.72
SCHEMBL29070637 0.72
SCHEMBL634197 0.72
SCHEMBL16914676 0.71 MAPT (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114773279-B Novel synthesis method of metconazole 浙江工业大学 2023-12-05 CN claimed
CN-118084640-A Preparation method of metconazole key intermediate 5- (4-chlorophenyl) methyl-2, 2-dimethylcyclopentanone 临海市建新化工有限公司 2024-05-28 CN disclosed
US-20240148732-A1 TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISORDERS SCHRÖDINGER, INC. 2024-05-09 US disclosed
EP-4284804-A1 TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISORDERS Schrödinger, Inc. (US) 2023-12-06 EP disclosed
CN-114773279-B Novel synthesis method of metconazole 浙江工业大学 2023-12-05 CN disclosed
CN-114773279-B Novel synthesis method of metconazole 浙江工业大学 2023-12-05 CN disclosed
CN-117120442-A Tricyclic compounds useful for treating cancer, autoimmune disorders, and inflammatory disorders 薛定谔公司 2023-11-24 CN disclosed
WO-2022164789-A9 TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISORDERS SCHRÖDINGER, INC. (US) 2023-05-25 WO disclosed
WO-2022164789-A1 TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISODERS SCHRÖDINGER, INC. (US) 2022-08-04 WO disclosed
EP-2803358-B1 10,10-Dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure ALLERGAN INC (US) 2017-05-03 EP disclosed
US-20120045420-A1 COMPOSITIONS AND IMPROVED SOFT TISSUE REPLACEMENT METHODS ALLERGAN, INC. (US) 2012-02-23 US disclosed
US-20110172435-A1 Treatment Of Inflammatory Bowel Disease ALLERGAN, INC. (US) 2011-07-14 US disclosed
CN-102050811-A 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure ALLERGAN INC 2011-05-11 CN disclosed
CN-102050812-A 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure ALLERGAN INC 2011-05-11 CN disclosed
US-7855226-B2 Treating inflammatory bowel disease by administering prostaglandin derivatives such as (3-{(1R,4S,5S)-5-(3-chloro-benzo[b]thiophen-2-yl)-3-hydroxy-pent-1-enyl]-4-hydroxy-3,3-dimethyl-2-oxo-cyclopentylsulfanyl}-propylsulfanyl)-acetic acid methyl ester ALLERGAN, INC. (US) 2010-12-21 US disclosed
CN-1758915-A 10, 10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure ALLERGAN INC (US) 2006-04-12 CN disclosed
US-20050164992-A1 Treating inflammatory bowel disease by administering prostaglandin derivatives such as (3-{(1R,4S,5S)-5-(3-chloro-benzo[b]thiophen-2-yl)-3-hydroxy-pent-1-enyl]-4-hydroxy-3,3-dimethyl-2-oxo-cyclopentylsulfanyl}-propylsulfanyl)-acetic acid methyl ester ALLERGAN, INC. (US) 2005-07-28 US disclosed
US-6875787-B2 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure ALLERGAN, INC. (US) 2005-04-05 US disclosed
US-20040235958-A1 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure ALLERGAN, INC. 2004-11-25 US disclosed
US-20040157901-A1 10,10-DIALKYL PROSTANOIC ACID DERIVATIVES AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE ALLERGAN, INC. 2004-08-12 US disclosed